Freed Daniel M, Bessman Nicholas J, Kiyatkin Anatoly, Salazar-Cavazos Emanuel, Byrne Patrick O, Moore Jason O, Valley Christopher C, Ferguson Kathryn M, Leahy Daniel J, Lidke Diane S, Lemmon Mark A
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104-6059, USA.
Cell. 2017 Oct 19;171(3):683-695.e18. doi: 10.1016/j.cell.2017.09.017. Epub 2017 Oct 5.
Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways. Using crystallography and other approaches, we show how the EGFR ligands epiregulin (EREG) and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region. As a consequence, EREG or EPGN induce less stable EGFR dimers than EGF-making them partial agonists of EGFR dimerization. Unexpectedly, this weakened dimerization elicits more sustained EGFR signaling than seen with EGF, provoking responses in breast cancer cells associated with differentiation rather than proliferation. Our results reveal how responses to different EGFR ligands are defined by receptor dimerization strength and signaling dynamics. These findings have broad implications for understanding receptor tyrosine kinase (RTK) signaling specificity. Our results also suggest parallels between partial and/or biased agonism in RTKs and G-protein-coupled receptors, as well as new therapeutic opportunities for correcting RTK signaling output.
表皮生长因子受体(EGFR)调控许多关键的细胞程序,七种不同的激活配体以不同方式塑造细胞信号传导。通过晶体学和其他方法,我们展示了EGFR配体表皮调节素(EREG)和表皮生成素(EPGN)如何稳定EGFR细胞外区域的不同二聚体构象。因此,与表皮生长因子(EGF)相比,EREG或EPGN诱导的EGFR二聚体稳定性较低,使其成为EGFR二聚化的部分激动剂。出乎意料的是,这种减弱的二聚化引发的EGFR信号传导比EGF引发的更持久,在乳腺癌细胞中引发与分化而非增殖相关的反应。我们的结果揭示了对不同EGFR配体的反应是如何由受体二聚化强度和信号动力学决定的。这些发现对于理解受体酪氨酸激酶(RTK)信号特异性具有广泛意义。我们的结果还表明RTK和G蛋白偶联受体中的部分和/或偏向激动作用之间存在相似之处,以及纠正RTK信号输出的新治疗机会。